Celregen Therapeutics signed a $100 million agreement to in-license China rights for a novel therapy that uses induced Pluripotent Stem Cells to repair bullous keratopathy.
/PRNewswire/ Great Bay Bio (hereinafter referred to as "GBB") is pleased to announce today the completion of its USD 15M Pre-series B funding led by Tiger.
/PRNewswire/ Great Bay Bio (GBB), an AI-enabled biotechnology company, announces the participation of FutureX Capital in its Series A round fundraising..
/PRNewswire/ Great Bay Bio (GBB), an AI-enabled biotechnology company, announces the participation of FutureX Capital in its Series A round fundraising..